CEMP Cempra, Inc.

3.85
+0.00  (0%)
Previous Close 3.85
Open 3.85
Price To book 1.24
Market Cap 202.14M
Shares 52,503,000
Volume 551,302
Short Ratio 1.87
Av. Daily Volume 1,577,280

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due by the end of 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. [$$] Health-Care Investor Agent Capital Seeks $100 Million Fund
  2. ETFs with exposure to Cempra, Inc. : May 15, 2017
  3. Cempra Presents Data on Ophthalmic Solithromycin at ARVO
  4. Cempra, Inc. :CEMP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
  5. Edited Transcript of CEMP earnings conference call or presentation 28-Apr-17 12:45pm GMT
  6. Cempra loses executive, but eyes FDA feedback
  7. Today's Research Reports on Stocks to Watch: Cempra and PhaseRx
  8. Cempra reports 1Q loss
  9. Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update
  10. Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
  11. Cempra to Report First Quarter 2017 Financial Results
  12. Cempra to Present at the 16th Annual Needham & Company Healthcare Conference
  13. Cempra Withdraws Solithromycin MAA in Europe
  14. For Chapel Hill's Cempra, no European launch for now
  15. Biotech Premarket Movers: Cempra, Tesaro, Editas
  16. Cempra Withdraws Solithromycin Marketing Authorization Application in Europe
  17. ETFs with exposure to Cempra, Inc. : March 27, 2017
  18. Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  19. Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  20. With $230M in cash, Cempra’s “strategic business options” wide-ranging

SEC Filings

  1. EFFECT - Notice of Effectiveness 17802746
  2. POS AM - Post-Effective amendments for registration statement 17791682
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17791678
  4. 8-K - Current report 17791653
  5. 8-K - Current report 17791650
  6. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 17759366
  7. 8-K - Current report 17717581
  8. 8-K - Current report 17683979
  9. 8-K - Current report 17666504
  10. POS AM - Post-Effective amendments for registration statement 17660155